Next Article in Journal
How to Balance Prognostic Factors in Controlled Phase II Trials: Stratified Permuted Block Randomization or Minimization? An Analysis of Clinical Trials in Digestive Oncology
Next Article in Special Issue
A Locally Advanced NSCLC Patient Harboring a Rare KIF13A-RET Fusion Benefited from Pralsetinib: A Case Report
Previous Article in Journal
Abstracts of the 39th Annual CAPO Conference—Building Hope: Integrating Sustainable, Innovative and Accessible Care in Psychosocial Oncology 6 to 7 June 2024
Previous Article in Special Issue
Real-World Analysis of Post-Progression Treatment Patterns and Outcomes for EGFR Mutation-Positive Patients Treated with First-Line Osimertinib
 
 
Review

Article Versions Notes

Curr. Oncol. 2024, 31(6), 3495-3512; https://doi.org/10.3390/curroncol31060258
Action Date Notes Link
article xml file uploaded 17 June 2024 09:42 CEST Original file -
article xml uploaded. 17 June 2024 09:42 CEST Update -
article pdf uploaded. 17 June 2024 09:42 CEST Version of Record -
article html file updated 17 June 2024 09:45 CEST Original file -
article xml file uploaded 17 June 2024 09:53 CEST Update -
article xml uploaded. 17 June 2024 09:53 CEST Update https://www.mdpi.com/1718-7729/31/6/258/xml
article pdf uploaded. 17 June 2024 09:53 CEST Updated version of record https://www.mdpi.com/1718-7729/31/6/258/pdf
article html file updated 17 June 2024 09:55 CEST Update https://www.mdpi.com/1718-7729/31/6/258/html
Back to TopTop